Cargando…

Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries

BACKGROUND: Fremanezumab (TEV-48125) is a fully humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) that has shown positive results in the prevention of episodic migraine and chronic migraine. Previous preclinical studies have revealed CGRP antagonistic effects on intracr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohlsson, Lena, Kronvall, Erik, Stratton, Jennifer, Edvinsson, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091427/ https://www.ncbi.nlm.nih.gov/pubmed/30109438 http://dx.doi.org/10.1186/s10194-018-0905-8

Ejemplares similares

The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
por: Dux, Mária, et al.
Publicado: (2022)

The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
por: Vogler, Birgit, et al.
Publicado: (2023)

Semi-Automated Recording of Facial Sensitivity in Rat Demonstrates Antinociceptive Effects of the Anti-CGRP Antibody Fremanezumab
por: Benedicter, Nicola, et al.
Publicado: (2023)

CGRP in Primary Headaches
por: Edvinsson, Lars
Publicado: (2001)

Differential inhibitory response to telcagepant on αCGRP induced vasorelaxation and intracellular Ca(2+) levels in the perfused and non-perfused isolated rat middle cerebral artery
por: Erdling, André, et al.
Publicado: (2017)

Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
por: Haanes, Kristian Agmund, et al.
Publicado: (2020)

Calcitonin Gene-Related Peptide (CGRP) in Cerebrovascular Disease
por: Edvinsson, Lars
Publicado: (2002)

Expression and Characterization of Purinergic Receptors in Rat Middle Meningeal Artery–Potential Role in Migraine
por: Haanes, Kristian Agmund, et al.
Publicado: (2014)

Blocking CGRP in migraine patients – a review of pros and cons
por: Deen, Marie, et al.
Publicado: (2017)

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab
por: De Luca, Ciro, et al.
Publicado: (2021)

Study of Cgrp-Receptors in Human Isolated Middle Meningeal Arteries Using Bibn4096Bs, Compound 1, and HαCgrp(8-37)
por: Razzaque, Z., et al.
Publicado: (2001)

Endothelin-converting-enzyme 1 inhibition and CGRP receptor recycling in human coronary and middle meningeal arteries
por: Labruijere, S, et al.
Publicado: (2013)

CGRP and CGRP receptors in human and rhesus monkey cerebellum
por: Eftekhari, S, et al.
Publicado: (2013)

Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system
por: Eftekhari, S, et al.
Publicado: (2013)

Fremanezumab for migraine
Publicado: (2020)

Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache
por: Carmine Belin, Andrea, et al.
Publicado: (2020)

Expression of the CGRP Family of Neuropeptides and their Receptors in the Trigeminal Ganglion
por: Edvinsson, Lars, et al.
Publicado: (2020)

Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
por: Straube, Andreas, et al.
Publicado: (2023)

Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of rat
por: Tfelt-Hansen, Peer, et al.
Publicado: (2007)

Enhanced Vasodilator Responses to CGRP (Calcitonin Gene-Related Peptide) in Subcutaneous Arteries in Human Hypertension
por: Lind, H., et al.
Publicado: (2001)

The Responses to CGRP in the Territory of the Posterior Cerebral Artery in Migraine
por: Visočnik, Darja, et al.
Publicado: (2022)

Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds
por: Grände, Gustaf, et al.
Publicado: (2014)

Inhibition of PKC activity blocks the increase of ET(B )receptor expression in cerebral arteries
por: Henriksson, Marie, et al.
Publicado: (2006)

Fremanezumab: First Global Approval
por: Hoy, Sheridan M.
Publicado: (2018)

A Novel Nonpeptide CGRP Receptor Antagonist, ‘Compound 1’ (WO98/11128) Is a High Affinity Competitive Antagonist at the CGRP1 Receptor in Human Coronary Arteries
por: Hasbak, P., et al.
Publicado: (2001)

Calcitonin gene‐related peptide (CGRP) is a key molecule released in acute migraine attacks—Successful translation of basic science to clinical practice
por: Edvinsson, Lars
Publicado: (2022)

Native CGRP Neuropeptide and Its Stable Analogue SAX, But Not CGRP Peptide Fragments, Inhibit Mucosal HIV-1 Transmission
por: Mariotton, Jammy, et al.
Publicado: (2021)

Correction to: Fremanezumab: First Global Approval
por: Hoy, Sheridan M.
Publicado: (2019)

Fremanezumab in the treatment of migraines: evidence to date
por: Robblee, Jennifer, et al.
Publicado: (2019)

Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level
por: Eftekhari, Sajedeh, et al.
Publicado: (2011)

Preliminary evidence that blocking the uptake of placenta-derived preeclamptic extracellular vesicles protects the vascular endothelium and prevents vasoconstriction
por: Erlandsson, Lena, et al.
Publicado: (2023)

Rodent behavior following a dural inflammation model with anti-CGRP migraine medication treatment
por: Reducha, Philip V., et al.
Publicado: (2023)

Amylin: Localization, Effects on Cerebral Arteries and on Local Cerebral Blood Flow in the Cat
por: Edvinsson, Lars, et al.
Publicado: (2001)

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
por: Root, Shane, et al.
Publicado: (2023)

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma
por: Kawamura, Shin, et al.
Publicado: (2022)

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
por: Favoni, Valentina, et al.
Publicado: (2019)

Migraine therapeutics differentially modulate the CGRP pathway
por: Bhakta, Minoti, et al.
Publicado: (2021)

C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system
por: Edvinsson, Jacob C. A., et al.
Publicado: (2019)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
por: Nowaczewska, Magdalena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_29k3rnhhd5tjtl72os5t3oi25o